Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.4400 -0.0199 (-4.33%)
Official Closing Price Updated: 8:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,635,138
Open 0.4550
Bid (Size) 0.4400 (10)
Ask (Size) 0.4497 (10)
Prev. Close 0.4599
Today's Range 0.4001 - 0.4694
52wk Range 0.2649 - 1.160
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Psychedelic Stock Gainers And Losers From February 3, 2023
 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 2, 2023
 
Via Benzinga

Performance

YTD
+45.21%
+45.21%
1 Month
+36.22%
+36.22%
3 Month
-3.91%
-3.91%
6 Month
-38.79%
-38.79%
1 Year
-58.10%
-58.10%

More News

Read More
Psychedelic Stock Gainers And Losers From February 1, 2023
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule
Via Investor Brand Network
Cybin Approved For First In-Human Dosing Of DMT Molecule CYB004, Milestone For Anxiety Disorder Treatment
Via Benzinga
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
From Cybin Inc.
Via Business Wire
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
Via Benzinga
The "Multi-Bagger" Portfolio Update: Week Ending January 27
Via Talk Markets
Largest Psychedelic Stocks +1.2% This Week; Now +16.1% YTD
Via Talk Markets
Cybin, GH Research Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 26, 2023
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day
Via Investor Brand Network
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
Via FinancialNewsMedia
Topics Economy
Exposures Supply Chain
Cybin to Host Virtual R&D Day on February 28, 2023
From Cybin Inc.
Via Business Wire
Biomind Labs, Intelgenx Technologies Among Top Psychedelic Movers Of Today
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2023
Via Benzinga
Psychedelic Stock Gainers And Losers From January 23, 2023
Via Benzinga
Largest Psychedelic Stocks +3% This Week; Now +15% YTD
Via Talk Markets
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From January 19, 2023
Via Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Cybin Touts Promising Results From Sponsored Kernel Flow Study Measuring Psychedelic Effects On The Brain
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Promising Results from Kernel Flow(R) Feasibility Study
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.